Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics) - Volume 7, Issue 4, 2009

Full text available

Nanotechnology and personalized medicine are two of the most rapidly emerging areas of biomedical research, as well as two of the most promising technologies for improving health care and health outcomes. They are also rapidly converging in numerous current and future clinical applications. Examples include the use of nanotechnology for improved DNA sequencing and SNP analysis, the development of nano-the Read More

Since the completion of the Human Genome Project, increasing scrutiny has focused on patterns of genetic variation among global populations and their association with disease and human traits. This paper addresses emerging techniques to identify genetic differences, including admixture mapping and the use of ancestry informative markers (AIMS), towards controlling population substructure in genetic association studies. Read More

Dr. Young-Ki Paik directs the Yonsei Proteome Research Center in Seoul, Korea and was elected as the President of the Human Proteome Organization (HUPO) in 2009. In the December 2009 issue of the Current Pharmacogenomics and Personalized Medicine (CPPM), Dr. Paik explains the new field of pharmacoproteomics and the approaching wave of “proteomics diagnostics” in relation to personalized medicine, HUPO Read More

Variation in the behavior of drugs between people, and variation in drug behavior in a given patient over time, have both presented us with challenging problems in optimal description of such behavior as well as challenges of how best to act on such information. New high-throughput genotyping methods and measurement of variations in gene expression over time present us with issues of 1) how best to use such info Read More

HER2 is over-expressed in approximately 25% to 30% of human metastatic breast cancers, primarily due to gene amplification. There are currently two HER2-targeted therapies approved for clinical use, the monoclonal HER2 antibody trastuzumab and the EGFR/HER2 dual tyrosine kinase inhibitor lapatinib. Although both agents show clinical benefit in a subset of patients with metastatic breast cancer, many patients with H Read More

Whether theranostic testing to discern person-to-person and population differences in drug metabolism pathways offers clinical guidance in oncology for fluoropyrimidines such as 5-fluorouracil (5-FU) remains an open question. Extensive basic and clinical studies have been performed over the past several decades with regard to personalizing treatment with fluoropyrimidines, optimizing patients' quality of life and redu Read More

Across the translational research continuum from biomarker discovery to public health research, “costeffectiveness” considerations are crucial, and can significantly impact the adoption of personalized medicine innovations. Cost-effectiveness is concerned with providing evidence to compare the (economic) costs and the health outcomes of competing health interventions or technologies. This also affects translationa Read More

Pharmacogenetics has its roots in the 1950s with pioneering studies of monogenic variations in drug metabolism and pharmacokinetics. With the availability of high-throughput genomics technologies and the completion of the Human Genome Project in 2003, we are now in the postgenomics era. This transition is increasingly marked with study of polygenic and multifactorial traits such as common complex human diseases as Read More

Full text available

Due to oversight on the part of the authors, G.I. Liou, A.B. El-Remessy, A.S. Ibrahim, R.B. Caldwell, Y.M. Khalifa, A. Gunes and J.J. Nussbaum., incomplete funding information was published in the review entitled “Cannabidiol as a Putative Novel Therapy for Diabetic Retinopathy: A Postulated Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development”, Current Pharmacogenomics and Personalized Medic Read More